Rising from the Ashes
MDCO's Cangrelor Succeeds in Phase III PHOENIX Study
By Jennifer Boggs
Thursday, January 10, 2013
Despite a clinical setback in 2009, when two massive Phase III trials of cangrelor were halted for lack of apparent efficacy, the antiplatelet candidate is back on track, as The Medicines Co. reported positive results from a new Phase III study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.